U.S. Liposomal Doxorubicin Market
Overview
Liposomal doxorubicin is a chemotherapy drug that is administered intravenously to treat AIDS-related Kaposi’s sarcoma, bosom disease, ovarian malignant growth, and other strong cancers. The liposome drug conveyance frameworks can alter the pharmacokinetics and bio-circulation of cytostatic specialists. They increase the convergence of the medication delivered to neoplastic tissue and diminish the openness of typical tissue to the medication. This medication is a kind of anthracycline anti-tumor anti-toxin, otherwise called Doxil and doxorubicin hydrochloride liposome. Measurements of doxorubicin hydrochloride liposome rely on a few elements, including height and weight, general wellbeing or other medical conditions, and the sort of malignant growth such as ovarian disease, AIDS-related kaposi’s sarcoma, and various myeloma.
The U.S. liposomal doxorubicin market had a valuation of US$ 140.0 million in 2020 and is anticipated to reach US$ 192.9 million by 2027, displaying a CAGR of 4.7% over the gauge period (2020-2027).
Get Full PDF Sample Copy of Report: (Including Full TOC, List of Tables& Figures, Chart) @ https://www.coherentmarketinsights.com/insight/request-pdf/4508
Drivers
The rising endorsement of nonexclusive items is supposed to drive the U.S. liposomal doxorubicin market’s development.
The rising endorsement of conventional results of liposomal doxorubicin from administrative specialists is supposed to increase interest in liposomal doxorubicin, and this is additionally expected to drive the development of the U.S. liposomal doxorubicin market. In March 2017, Dr. Reddy’s Laboratories Ltd. reported that it got the U.S. Food and Drug Administration’s endorsement to launch doxorubicin hydrochloride liposome infusion in the U.S., which is a conventional variant of Janssen Products’ Doxil (doxorubicin hydrochloride liposome infusion). Doxorubicin hydrochloride liposome infusion is shown for the therapy of ovarian disease and is regulated intravenously in patients.
Effect of the Coronavirus (COVID-19) Pandemic
Since the COVID-19 infection episode in December 2019, the sickness has spread to more than 100 nations across the globe and the World Health Organization has pronounced it a general wellbeing crisis. The private medical care area is one of the areas that has been significantly affected by the pandemic. The lockdowns in different nations have put a monetary weight on the private medical services area. Medical service suppliers are confronting difficulties concerning labor, gear, consumables, and different assets to guarantee the security of patients with different illnesses and short-term patient visits, among others. In addition, the pandemic has harmed the turn of events, creation, and supply of medications and has impacted the development of the U.S. liposomal doxorubicin market and medical care fragments of different organizations across the globe. This has prompted the conclusion of modern foundations, with the exception of the assembling of fundamental wares and disturbance in the store network of items. Accordingly, the COVID-19 pandemic is supposed to somewhat disturb the R&D exercises in the medical services area as well as in the U.S. liposomal doxorubicin market.
To Get more information Request a Free Sample Copy of Report @ https://www.coherentmarketinsights.com/insight/request-sample/4508
Restriction
A few aftereffects related to the liposomal doxorubicin drug are supposed to hamper the development of the U.S. liposomal doxorubicin market. The aftereffects incorporate an increased chance of disease, shortness of breath and pale coloring, swelling, draining gums and nosebleeds, sleepiness and shortcoming (exhaustion) during and after treatment, redness, touchiness, and stripping of the hands and feet, a deficiency of weight, and looseness of the bowels, among others.
Competitive Landscape
Key companies contributing to the U.S. liposomal doxorubicin market include Baxter International, Inc., Johnson & Johnson, Dr. Reddy’s Laboratories, Inc., and Sun Pharmaceutical Industries Ltd.
Purchase This Premium Report With Flat USD 2000 OFF @ https://www.coherentmarketinsights.com/promo/buynow/4508
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Drug Type
- Market Snapshot, By Cancer Type
- Market Snapshot, By States
- Market Opportunity Map
- Report Description
- U.S. Liposomal Doxorubicin Market Insights
- Drivers
- Restraints
- Opportunity
- Impact Analysis
- Demand Analysis
- Regulatory Scenario
- Key Developments
- PEST Analysis
- Pricing Analysis
- Competitive Snapshot
- Pipeline Analysis
- Major Distributors
- Reimbursement Scenario
- Epidemiology
- Alternative Treatments
- Liposomal Doxorubicin Import and Export
- Global Liposomal Doxorubicin Market Overview
- Definition
- Impact Analysis
- Market Overview
- Regional Share
- S. & Global Market Comparison
- U.S. Liposomal Doxorubicin Market – Impact of Coronavirus (Covid-19) Pandemic
- Impact on Supply Chain
- Impact on Demand
- U.S. Liposomal Doxorubicin Market, By Drug Type, 2016 – 2027 (US$ Million)
- Introduction
- Market Share Analysis, 2020 and 2027(%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Branded
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027(US$ Million)
- Generic
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027(US$ Million)
- Introduction
- U.S. Liposomal Doxorubicin Market, By Cancer Type, 2016 – 2027 (US$ Million)
- Introduction
- Market Share Analysis, 2020 and 2027(%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Segment Trends
- Ovarian Cancer
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027(US$ Million)
- AIDS-related Kaposi’s Sarcoma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027(US$ Million
- Multiple Myeloma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027(US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027(US$ Million)
- Introduction
- U.S. Liposomal Doxorubicin Market, By States, 2016 – 2027 (US$ Million)
- Introduction
- Market Share Analysis, 2020 and 2027(%)
- Y-o-Y Growth Analysis, 2017 – 2027
- Country at Trends
- California
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Million)
- Texas
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Million)
- Florida
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Million)
- New York
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Million)
- Pennsylvania
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Million)
- Illinois
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Million)
- Ohio
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Million)
- Georgia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Million)
- North Carolina
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Million)
- Michigan
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Million)
- New Jersey
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Million)
- Virginia
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Million)
- Washington
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Million)
- Arizona
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Million)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2016–2027, (US$ Million)
- Introduction
𝐀𝐛𝐨𝐮𝐭 𝐂𝐨𝐡𝐞𝐫𝐞𝐧𝐭 𝐌𝐚𝐫𝐤𝐞𝐭 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
𝐂𝐨𝐧𝐭𝐚𝐜𝐭 𝐔𝐬:
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837